Scinai (SCNI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.5M

Revenue (quarter)

$460,000.00

Revenue growth (year over year)

+145.99%

Gross profit (trailing twelve months)

−$3.8M

Gross margin

−252.32%

Net income (trailing twelve months)

−$2.6M

Net income (quarter)

−$2.0M

Net income growth (year over year)

+22.27%

Net margin

−174.78%

Return on equity

−26.53%

EPS (trailing twelve months)

—

Book value per share

$10.71

P/E (trailing twelve months)

—

Price to book

0.10

Debt to assets

31.69%

Payout ratio

—

Dividend yield

—

Company profile

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.

• Is Scinai (SCNI) profitable?

  No. Scinai reported a net loss of $2.6M over the trailing twelve months.

• How much revenue does Scinai (SCNI) make?

  Scinai generated $1.5M in revenue over the trailing twelve months, up 145.99% year over year.

• How do I buy stock in Scinai (SCNI)?

  SCNI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.